RxDoctor Payments Data

Sydney Dangelo, DO

Internal Medicine · la Mesa, CANPI 1770141061

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 73 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$369
  • Novo Nordisk$231
  • Boehringer Ingelheim$160
  • Empire Medical, Inc$125
  • AstraZeneca$113
  • Actelion Pharmaceuticals US, Inc.$55
  • plus $513 from 18 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,565 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$71,084
Medicare patients
148
Services billed
2,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$41,122
EliquisApixaban36$37,032
MounjaroTirzepatide28$29,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,360
JardianceEmpagliflozin13$20,391
FarxigaDapagliflozin Propanediol12$8,705
Atorvastatin Calcium184$1,864
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$1,635
Duloxetine Hcl56$1,529
Levothyroxine Sodium120$1,419
Albuterol Sulfate HfaAlbuterol Sulfate48$1,363
Losartan Potassium113$1,166
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst68$1,145
Omeprazole52$1,031
Ezetimibe17$914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$231$41,12221 claims
PfizerEliquis$54$37,03236 claims
Lilly USA, LLCMounjaro$369$29,17928 claims
Boehringer IngelheimJardiance$160$20,39113 claims
AstraZenecaFarxiga$113$8,70512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →